DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tarka (Trandolapril / Verapamil Hydrochloride Extended Release) - Summary



  • When pregnancy is detected, discontinue TARKA as soon as possible.
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity).


TARKA├é® (trandolapril/verapamil hydrochloride ER) combines a slow release formulation of a calcium channel blocker, verapamil hydrochloride, and an immediate release formulation of an angiotensin converting enzyme inhibitor, trandolapril.

TARKA is indicated for the treatment of hypertension.

This fixed combination drug is not indicated for the initial therapy of hypertension (DOSAGE and ADMINISTRATION).

In using TARKA, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS: Neutropenia/Agranulocytosis).
See all Tarka indications & dosage >>


Media Articles Related to Tarka (Trandolapril / Verapamil)

Pharmacists help patients with hypertension
Source: Hypertension News From Medical News Today [2015.07.31]
If you have hypertension, it pays to include a pharmacist in a medical care team.

Food container plastics linked to hypertension
Source: Hypertension News From Medical News Today [2015.07.09]
Plastic food containers and wraps containing phthalates were associated with hypertension and insulin resistance in two new studies investigating the chemicals.

Hypertension, high cholesterol, other heart disease risk factors increasing In Asia
Source: Cholesterol News From Medical News Today [2015.07.07]
Research efforts, data collection vital to improved treatmentThe prevalence of cardiovascular risk factors like hypertension, high cholesterol, and diabetes have been decreasing in the United...

Two new studies on the connection between hypertension and cognitive decline
Source: Hypertension News From Medical News Today [2015.07.03]
With the number of individuals affected by cognitive decline expected to rise over the next few decades, investigating its potential causes is of major public health interest.

Portal Hypertension
Source: MedicineNet Cirrhosis Specialty [2015.05.29]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 5/29/2015 12:00:00 AM

more news >>

Published Studies Related to Tarka (Trandolapril / Verapamil)

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). [2005.07]
BACKGROUND: The INternational VErapamil SR-Trandolapril Study (INVEST), a prospective, randomized, antihypertensive trial, found that two different medication regimens produced similar blood pressure (BP) control with equivalent cardiovascular (CV) outcomes (death from any cause, nonfatal myocardial infarction [MI], or nonfatal stroke). HYPOTHESIS: The study was undertaken to investigate whether differences exist by global regions in demographics, treatment, and outcomes in the INVEST trial... CONCLUSIONS: In INVEST, regional differences in medication utilization, BP control, and CV outcomes were identified. These disparities warrant further investigation to define appropriate care for patients with hypertension and stable CAD from an international public health perspective.

The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. [2004.07]
CONCLUSIONS: Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients. This effect on proteinuria is not related with blood pressure reduction.

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. [2003.12.03]
CONTEXT: Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials. OBJECTIVE: To compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS)... CONCLUSION: The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients.

The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. [2003.07]
BACKGROUND: We tested whether the combination of verapamil (V) or amlodipine (A) with trandolapril (T) affected proteinuria differently from T alone in patients with nondiabetic nephropathies... CONCLUSION: In patients with nondiabetic proteinuric nephropathies treated with T, the combination of V or A does not significantly increase its antiproteinuric effect.

Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. [2003.05]
BACKGROUND: There is evidence that diuretics and beta blockers impair glucose tolerance, whereas calcium channel blockers and angiotensin converting enzyme blockers lack this metabolic effect. We compared the effect of a combination therapy with a nondihydropyridine calcium channel blocker plus an angiotensin converting enzyme inhibitor and a beta blocker plus a diuretic on hemoglobin A(1c) (Hb A(1c)) in patients with type 2 diabetes and mild-to- moderate hypertension... CONCLUSIONS: HbA(1c) and other parameters of short- and long-term glycemic control were in a more favorable range after antihypertensive treatment with verapamil SR plus trandolapril as compared with atenolol plus chlorthalidone.

more studies >>

Clinical Trials Related to Tarka (Trandolapril / Verapamil)

Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) [Active, not recruiting]
The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

Tarka« vs. Lotrel« in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) [Active, not recruiting]
The primary objective of this study is to determine if trandolapril/verapamil (Tarka«) is superior to amlodipine/benazepril (Lotrel«) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy

Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension [Active, not recruiting]
This study will investigate antihypertensive activity and safety profile of Tarka in Russian hypertension patients by ambulatory blood pressure measurement (ABPM)

INVEST: INternational VErapamil SR Trandolapril STudy [Completed]
Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).

Verapamil and Catamenial Epilepsy [Not yet recruiting]
One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i. e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

more trials >>

Reports of Suspected Tarka (Trandolapril / Verapamil) Side Effects

Renal Failure Acute (11)Bradycardia (11)Hypotension (9)Hyperkalaemia (7)Dyspnoea (6)Asthenia (6)Renal Tubular Disorder (5)Drug Interaction (5)Nausea (5)Agitation (4)more >>


Based on a total of 1 ratings/reviews, Tarka has an overall score of 9. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.

Tarka review by 51 year old female patient

Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
Treatment Info
Condition / reason:   hypertension
Dosage & duration:   240/40 (dosage frequency: once daily) for the period of been taking for couple of years
Other conditions:   hypothyroidism
Other drugs taken:   synthyroid
Reported Results
Benefits:   very effectively reduced my blood pressure to a good level and has amitianed it for the 2+ years I have been taking it.
Side effects:   My lungs feel heavy at times and that produces a hacking cough. It's not all the time, just occasionally. It hasn't been bothersome enough to ask about changing it to something else yet.
Comments:   I'm taking one pill that contains two different blood pressure medications. It has been very effective in controlling my hypertension.

See all Tarka reviews / ratings >>

Page last updated: 2015-07-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015